BNP Paribas Financial Markets’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.66B | Sell |
16,777,726
-4,378,146
| -21% | -$592M | 0.92% | 15 |
|
|
2026
Q1 | $2.7B | Buy |
21,155,872
+4,568,518
| +28% | +$570M | 1.31% | 7 |
|
|
2025
Q4 | $2.02B | Buy |
16,587,354
+10,622,553
| +178% | +$1.22B | 0.92% | 15 |
|
|
2025
Q3 | $598M | Sell |
5,964,801
-1,645,780
| -22% | -$148M | 0.32% | 43 |
|
|
2025
Q2 | $631M | Sell |
7,610,581
-2,490,899
| -25% | -$199M | 0.36% | 38 |
|
|
2025
Q1 | $819M | Sell |
10,101,480
-1,783,010
| -15% | -$159M | 0.48% | 29 |
|
|
2024
Q4 | $1.07B | Buy |
11,884,490
+8,873,467
| +295% | +$860M | 0.6% | 21 |
|
|
2024
Q3 | $297M | Sell |
3,011,023
-2,271,280
| -43% | -$223M | 0.2% | 93 |
|
|
2024
Q2 | $490M | Buy |
5,282,303
+1,629,380
| +45% | +$146M | 0.4% | 48 |
|
|
2024
Q1 | $347M | Buy |
3,652,923
+2,951,022
| +420% | +$274M | 0.3% | 65 |
|
|
2023
Q4 | $62.7M | Sell |
701,901
-2,214,536
| -76% | -$164M | 0.07% | 297 |
|
|
2023
Q3 | $213M | Buy |
2,916,437
+201,302
| +7% | +$16.1M | 0.27% | 62 |
|
|
2023
Q2 | $226M | Buy |
2,715,135
+1,641,600
| +153% | +$137M | 0.28% | 57 |
|
|
2023
Q1 | $81.8M | Buy |
1,073,535
+583,998
| +119% | +$48.5M | 0.11% | 176 |
|
|
2022
Q4 | $40.6M | Sell |
489,537
-1,594,745
| -77% | -$129M | 0.06% | 386 |
|
|
2022
Q3 | $165M | Sell |
2,084,282
-1,691,513
| -45% | -$143M | 0.26% | 64 |
|
|
2022
Q2 | $280M | Sell |
3,775,795
-610,217
| -14% | -$45.8M | 0.44% | 35 |
|
|
2022
Q1 | $394M | Buy |
4,386,012
+3,254,587
| +288% | +$301M | 0.53% | 21 |
|
|
2021
Q4 | $127M | Sell |
1,131,425
-4,082,782
| -78% | -$492M | 0.18% | 110 |
|
|
2021
Q3 | $655M | Sell |
5,214,207
-590,385
| -10% | -$76M | 0.93% | 8 |
|
|
2021
Q2 | $786M | Sell |
5,804,592
-886,020
| -13% | -$116M | 1.04% | 6 |
|
|
2021
Q1 | $908M | Buy |
6,690,612
+6,432,956
| +2,497% | +$963M | 1.33% | 8 |
|
|
2020
Q4 | $36.3M | Sell |
257,656
-4,453,999
| -95% | -$570M | 0.07% | 301 |
|
|
2020
Q3 | $525M | Sell |
4,711,655
-3,079,589
| -40% | -$345M | 0.75% | 17 |
|
|
2020
Q2 | $872M | Sell |
7,791,244
-820,053
| -10% | -$80.8M | 1.54% | 6 |
|
|
2020
Q1 | $667M | Buy |
8,611,297
+7,511,297
| +683% | +$665M | 1.37% | 7 |
|
|
2019
Q4 | $105M | Sell |
1,100,000
-10,511,013
| -91% | -$909M | 0.19% | 108 |
|
|
2019
Q3 | $885M | Buy |
11,611,013
+2,529,967
| +28% | +$210M | 1.57% | 3 |
|
|
2019
Q2 | $796M | Buy |
9,081,046
+3,056,439
| +51% | +$261M | 1.59% | 3 |
|
|
2019
Q1 | $545M | Buy |
6,024,607
+3,653,555
| +154% | +$311M | 1.18% | 8 |
|
|
2018
Q4 | $170M | Sell |
2,371,052
-1,155,040
| -33% | -$93.1M | 0.4% | 40 |
|
|
2018
Q3 | $338M | Buy |
3,526,092
+416,199
| +13% | +$40.4M | 0.5% | 25 |
|
|
2018
Q2 | $296M | Buy |
3,109,893
+114,787
| +4% | +$10.5M | 0.49% | 30 |
|
|
2018
Q1 | $263M | Sell |
2,995,106
-532,522
| -15% | -$48.6M | 0.49% | 31 |
|
|
2017
Q4 | $299M | Sell |
3,527,628
-485,732
| -12% | -$40.7M | 0.53% | 27 |
|
|
2017
Q3 | $347M | Sell |
4,013,360
-1,401,640
| -26% | -$112M | 0.85% | 13 |
|
|
2017
Q2 | $418M | Buy |
5,415,000
+1,599,460
| +42% | +$113M | 1.26% | 7 |
|
|
2017
Q1 | $265M | Buy |
3,815,540
+1,608,170
| +73% | +$108M | 0.7% | 22 |
|
|
2016
Q4 | $131M | Sell |
2,207,370
-978,980
| -31% | -$60.4M | 0.61% | 28 |
|
|
2016
Q3 | $211M | Sell |
3,186,350
-747,070
| -19% | -$46.2M | 0.87% | 19 |
|
|
2016
Q2 | $213M | Buy |
3,933,420
+1,599,830
| +69% | +$87.7M | 0.96% | 12 |
|
|
2016
Q1 | $121M | Buy |
2,333,590
+850,420
| +57% | +$44.2M | 0.51% | 37 |
|
|
2015
Q4 | $104M | Sell |
1,483,170
-625,090
| -30% | -$42.6M | 0.51% | 36 |
|
|
2015
Q3 | $131M | Sell |
2,108,260
-1,650,080
| -44% | -$130M | 0.33% | 42 |
|
|
2015
Q2 | $316M | Buy |
3,758,340
+2,249,811
| +149% | +$175M | 0.88% | 16 |
|
|
2015
Q1 | $113M | Buy |
1,508,529
+1,499,880
| +17,342% | +$105M | 0.31% | 52 |
|
|
2014
Q4 | $538K | Buy |
8,649
+117
| +1% | +$6.67K | ﹤0.01% | 1106 |
|
|
2014
Q3 | $444K | Buy |
8,532
+144
| +2% | +$7.34K | ﹤0.01% | 1575 |
|
|
2014
Q2 | $431K | Buy |
+8,388
| New | +$378K | ﹤0.01% | 1546 |
|
Other funds holding XBI
JFG
BNP Paribas Financial Markets's XBI Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 21% in Q2 2026, selling an estimated $592M and leaving 16,777,726 shares worth $2.66B. The position accounts for 0.92% of the portfolio, ranked #15.
BNP Paribas Financial Markets first reported a position in XBI in Q2 2014 and has held it in 49 quarters since. The position peaked at $2.7B in Q1 2026. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- BNP Paribas Financial Markets held 16,777,726 shares of State Street SPDR S&P Biotech ETF worth $2.66B as of Q2 2026.
- BNP Paribas Financial Markets sold 4,378,146 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $592M.
- State Street SPDR S&P Biotech ETF made up 0.92% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #15 holding.
- BNP Paribas Financial Markets first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and has held it in 49 quarters since.
- BNP Paribas Financial Markets's State Street SPDR S&P Biotech ETF position peaked at $2.7B in Q1 2026.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.